Therapy pattern of bronchodilators in chronic obstructive pulmonary disease (COPD) patients with acute exacerbations
DOI:
https://doi.org/10.46542/pe.2023.234.224227Keywords:
Acute exacerbation, Bronchodilator, Chronic obstructive pulmonary disease, Chronic respiratory diseaseAbstract
Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a worsening condition of acute respiratory symptoms caused by microbial infection, increased air pollution, and fatigue.
Objective: This study determines the pattern of bronchodilators in patients with acute exacerbations of COPD.
Method: This study was observational, using the health medical records of patients with COPD at the Universitas Airlangga Hospital, Surabaya. It was conducted between January-December 2019 on male patients who received bronchodilator therapy until discharge and were from age 40 and older.
Result: A total of 48 patients met the inclusion criteria. The most commonly used bronchodilator therapy for inpatients was the combination of ipratropium bromide/salbutamol sulfate 0.5 mg/2.5 mg through inhalation in 63.64%. The most frequently used bronchodilator for discharge was salbutamol sulfate 2-4 mg orally in 87.50%.
Conclusion: Therapy for acute exacerbation of COPD using a combination of ipratropium bromide/salbutamol sulfate as a preventive therapy is in line with the GOLD guidelines.
References
Aaron, D.S., Vandemheen, L.K., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O’Donnell, D., McIvor, A., Sharma, S., Bishop, G., Anthony, J., Cowie, R., Field, S., Hirsch, A., Hernandez, P., Rivington, R., Road, J., Hoffstein, V., Hodder, R., Marciniuk, D., McCormack, D., Fox, G., Cox, G., Prins, B.H., Ford, G., Bleskie, D., Doucette, S., Mayers, I., Chapman, K., Zamel, N., & FitzGerald, M. (2007). Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Annals of Internal Medicine, 146(8), 545–555. https://doi.org/10.7326/0003-4819-146-8-200704170-00152
American Society of Health-System Pharmacists. (2012). AHFS grug information. Available at: https://www.worldcat.org/title/ahfs-drug-information-2012/oclc/774043698
American Lung Association. (2021). COPD causes and risk factors. Available at: https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/whatcauses-copd
Antus, Balazs. (2013). Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review. ISRN Pulmonology 2013, 1–11. https://doi.org/10.1155/2013/582807
Barnes, J.P. (2013) . Pulmonary pharmacology . In L. Brunton & B.K.B. Chabner (Eds.), Goodman & Gilman's: The pharmacological basis of therapeutics.
(13th ed., pp.1031-1090). The McGraw-Hill Companies. https://accessmedicine.mhmedical.com/content.aspx?bookid=2189§ionid=172481165
Bourdet, V.S., & Williams, M.D. (2017). Chronic obstructive pulmonary disease. In DiPiro, T.J.P.M., Talbert, L.R., Yee, C.G., Matzke,R.G., Wells, G.B. (Eds.), Pharmacotherapy: A pathophysiologic approach (10th ed). Available at: https://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=146058280
Brown, W.S., & Braman, S. (2020). Recent Advances in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Medical Clinics of North America, 104(4), 615–630. https://doi.org/10.1016/j.mcna.2020.02.003
Criner, J.G., Bourbeau, J., Diekemper, L.R., Ouellette, R.D., Goodridge, D., Hernandez, P., Curren, K., Balter, S.M., Bhutani, M., Camp, G.P., Celli, R.B., Dechman, G., Dransfield, T.M, Fiel, B.S, Foreman, G.M, Hanania, A.N, Ireland, K.B., Marchetti, N., Marciniuk, D.D., Mularski, A.R., Ornelas, J., Road, D.J, & Stickland, K.M. (2015). Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest, 147(4), 894–942. https://doi.org/10.1378/chest.14-1676
Cushen, B., Sulaiman, I., Donoghue, N., Langan, D., Cahill, T., Nic Dhonncha, E., Healy, O., Keegan, F., Browne, M., & O'Regan, A. (2016). High prevalence of obstructive lung disease in non-smoking farmers: The Irish farmer's lung health study. Respiratory Medicine, 115, 13–19. https://doi.org/10.1016/j.rmed.2016.04.006
Dong, Y., Hsu, C., Li, Y., Chang, C., & Lai, M. (2015). Bronchodilators use in patients with COPD. International Journal of COPD, 10(1), 1769–1779. https://doi.org/10.2147/COPD.S86198
GOLD. (2020). GOLD Report 2020. Global Initiative for Chronic Obstructive Lung Disease, 141. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
Kemenkes, R.I. (2008). Pedoman pengendalian penyakit paru obstruktif kronik. Available at: https://persi.or.id/wp-content/uploads/2020/11/kmk10222008.pdf
Kemenkes, R.I. (2013). Riset kesehatan dasar (Rakesdas). https://pusdatin.kemkes.go.id/resources/download/general/HasilRiskesdas2013.pdf
Li, X., Wu, Z., Xue, M., & Du, W. (2020). Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: A prospectively observational study. Chronic Respiratory Disease, 17. https://doi.org/10.1177/1479973120916184
Spannella, F., Giulietti, F., Cocci, G., Landi, L., Lombardi, E.F., Borioni, E., Cenci, A., Giordano, P., & Sarzani, R. (2019). Acute exacerbation of chronic obstructive pulmonary disease in oldest adults: Predictors of in-hospital mortality and need for post-acute care. Journal of the American Medical Directors Association, 20(7), 893–898. https://doi.org/10.1016/j.jamda.2019.01.125
Thomas, V., Gefen, E., Gopalan, G., Mares, R., McDonald, R., Yau Ming, W.S., & Price, B.D. (2017). Ipratropium/salbutamol comparator versus originator for chronic obstructive pulmonary disease exacerbations: USA observational cohort study using the clinformaticsTM health claims database. Pulmonary Therapy, 3(1), 187–205. https://doi.org/10.1007/s41030-017-0041-7
